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Part I. Creation of stain for CALAA-01 
 
Materials 
Methoxy-PEG-thiol (MW 1000 g/mol) was purchased from Laysan Bio (Arab, AL). SPDP-
dPEGTM12-NHS (MW 912.08 g/mol) ester was purchased from Quanta Biodesign (Powell, OH). 
5 nm spherical gold nanoparticles were obtained from Nanopartz (Salt Lake City, UT). 
 
Methods 
Preparation of SPDP-dPEGTM12-AD (see Scheme SI 1) 
To a solution of SPDP-dPEGTM12-NHS (100 mg, 0.11 mmol) in 3 ml of anhydrous 
dichloromethane was added adamantanemethylamine (0.11 mmol, 21 µl). The solution was 
stirred for 16 h at room temperature, after which the solvent was removed and the product dried 
under vacuuo. (MALDI-TOF) [M+Na]+ 984.08, [M+K]+ 1000.16 
 
 
 
Scheme SI 1: Synthesis of SPDP-dPEGTM12-AD 
 
 
PEGylation of 5 nm gold nanoparticles with SPDP-dPEGTM12-AD (Au-PEG-AD) 
To a pre-sonicated 1 ml solution of 5 nm gold nanoparticles (1013 particles ml-1) was added 
mPEG-thiol (14 µg, 14 nmol) and SPDP-dPEGTM12-AD (16 µg, 14 nmol). The solution was 
vortexed for 30 min and diluted to 4 ml with deionized water. The resulting 4 ml solution was 
diafiltered twice with a 10 kDa membrane (Millipore) and finally resuspended to 1 ml.  
 
PEGylation of 5 nm gold nanoparticles with methoxy-PEG-thiol (Au-PEG) 
To a pre-sonicated 1 ml solution of 5 nm gold nanoparticles (1013 particles ml-1) was added 
methoxy-PEG-thiol (28 µg, 28 nmol). The solution was vortexed for 30 min and diluted to 4 ml 
with deionized water. The resulting 4 ml solution was diafiltered twice with a 10 kDa membrane 
(Millipore) and finally resuspended to 1 ml.  
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Part II: Principle of staining  
 
A schematic representation of the interactions between the Au-PEG-AD particles and CALAA-
01 is shown in Schematic SI 2. 
 
Key 
 
 
 
 
 
 
Scheme SI 2: Representation of the staining process of CALAA-01 by Au-PEG-AD particles. 
 
 
 
Part III: In vitro validation of binding of Au-PEG-AD to the siRNA-containing nanoparticles  
 
A sandwich ELISA assay was developed to test for the binding of the gold stain (Au-PEG-AD) 
onto the siRNA-containing nanoparticles.  
 
Materials 
• Coating buffer: 10 µg ml-1 mouse IgG against human transferrin (Bethyl Laboratories, 
Montgomery, TX) in 50 mM carbonate-bicarbonate buffer (pH = 9.6) 
• Wash buffer: 50 mM Tris, 140 mM NaCl, 0.05 % Tween 20, pH = 8  
• Blocking buffer: 50 mM Tris, 140 mM NaCl, 1 % bovine serum albumin (BSA), pH = 8  
• Targeted particle solution: Transferrin-targeted particles containing siRNA (0.5 mol % AD-PEG-
Tf ) in 150 mM phosphate buffered saline (PBS) 
• Staining solution: Au-PEG-AD or Au-PEG particles in 150 mM PBS   
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Method 
The entire ELISA procedure was conducted at room temperature with mild shaking on a plate shaker. Into 
each well of a 96-well ELISA plate was coated with 0.1 ml of coating buffer that contains the primary 
antibody, IgG against human transferrin for 1 h. Three rinses with 0.1 ml of wash buffer followed to 
remove unbound antibodies. Next, blocking with BSA by adding 0.2 ml of blocking buffer into each well 
took place for 1 hour, followed by three brief rinses with 0.1 ml of wash buffer. After that, each well was 
added with 0.1 ml of either targeted particle solution or 150 mM PBS as a negative control and incubated 
for 2 h. After five rinses with 0.1 ml of wash buffer to remove unbound targeted particles, each well was 
loaded with 0.1 ml of staining solution containing either Au-PEG-AD or Au-PEG at different 
concentrations and incubated for 2 h. Upon five rinses with 0.1 ml of wash buffer to remove unbound 
targeted particles, each well was loaded with 0.1 ml of 150 mM PBS for absorbance measurement at 520 
nm (surface plasmonic peak for 5 nm Au-PEG particles) using a Safire2 Microplate Reader (Tecan, 
Salzburg, Austria). Reported values are mean absorbance from duplicates of experiments.  
 
 
Results 
 
The binding of Au-PEG-AD to the siRNA-containing nanoparticles relies upon the interaction 
between ADs and the cyclodextrin (CD) in a dose dependent fashion.  
 
 
 
Figure S1: (A) The ELISA plate captures the red color due to binding of Au-PEG-AD onto 
targeted siRNA particles via specific CD-AD interactions. Legend: - A: no targeted nanoparticles 
+ gold particles (1012 # ml-1); B: targeted nanoparticles + gold particles (1012 # ml-1); C: targeted 
nanoparticles + gold particles (3x1012 # ml-1); D: targeted nanoparticles + gold particles (1013 # 
ml-1); E: targeted nanoparticles + gold particles (3x1013 # ml-1). (B) This graph demonstrates a 
dose-dependent binding of Au-PEG-AD onto siRNA-containing, CDP targeted nanoparticles 
(rows B to E in Figure S1A). As the negative control, the wells not loaded with any targeted 
nanoparticles do not show detectable gold absorbance (row A in Figure S1A). 
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Part IV: In vivo validation of binding of Au-PEG-AD to siRNA-containing nanoparticles in 
murine models 
 
The use of imaging techniques serves to ascertain whether Au-PEG-AD can recognize 
intravenously injected targeted, siRNA-containing nanoparticles in a mouse tumor tissue.  
 
Methods 
 
Tumor Formation and Systemic Delivery of siRNA-containing Nanoparticles 
 
All animal experiments were performed with sterile techniques and complied with the NIH 
Guidelines for Animal Care and as approved by the Caltech Institutional Animal Care and Use 
Committee. Neuro2A (mouse neuroblastoma) cells were cultured in complete growth medium 
(DMEM supplemented with 10 % fetal bovine serum (FBS), 100 units ml-1 penicillin, and 100 
units ml-1 streptomycin). In the right hind flank, four immunodeficient (NOD.CB17-Prkdcscid/J) 
mice (The Jackson Laboratory, Bar Harbor, ME) received subcutaneous implantation of N2A 
cells (at 106 cells per mouse per 0.1 ml of DMEM). Before injection, tumors reached 100-200 
mm3 in size, as determined by caliper measurements (0.5 x l x w2). Two mice received 
intravenous administration of siRNA-containing, cyclodextrin-based, targeted nanoparticles at a 
dose level of 10 mg siRNA kg-1 animal via the tail-vein. Formulated in 0.1 ml of 5 % glucose in 
water (D5W), the injected dose contained targeted nanoparticles carrying Cy3-labeled siRNA 
(20% of the total siRNA in the nanoparticles). As controls, two other mice received intravenous 
injections of 0.1 ml of D5W. Animal sacrifice by CO2 overdose took place 24 h after injection, 
followed by tumor extraction and immersion fixation in 4 % paraformaldehyde (PFA).   
 
 
Transmission Electron Microscopy  
 
PFA-fixed blocks (~ 1 mm3 in volume) of mouse tumor samples received fixation with 2.5 % 
glutaraldehyde (in 100 mM sodium cacodylate, pH = 7.4) for 2 h, post-stain by 1 % OsO4 at 4 °C 
for 2 h, and 0.9 % OsO4 and 3 % K3Fe(CN)6 at 4 °C for 2 h. Subsequent dehydration with an 
ethanol gradient and propylene oxide enabled the embedding tissue blocks polymerized from 
Epon 812 resins (EMS; Electron Microscopy Sciences, Hatfield, PA). 80 nm thick sections were 
deposited on carbon and formvar-coated, 200-mesh, nickel grids (EMS) and later stained with 3 
% uranyl acetate (SPI Supplies, West Chester, PA) and Reynolds lead citrate for visualization 
under a 120 kV BioTwin CM120 TEM (Philips). All electron micrographs are from randomly 
chosen facets of the tissue block.  
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Results 
 
Transmission electron microscopy confirms the existence of siRNA containing, targeted 
nanoparticles inside a mouse subcutaneous tumor.  
 
 
 
Figure S2: Transmission electron micrographs showed intracellular localization of siRNA-
containing, cyclodextrin-based, targeted nanoparticles (dark round objects – the siRNA within 
the nanoparticle is stained by the presence of the uranyl ions that bind to the nucleic acid) inside 
N2A cells of the tumor subcutaneously implanted in mice (same tumor tissue used for confocal 
fluorescence imaging in Figure 1). (Left) The proximity of targeted nanoparticles to the nucleus 
shows their intracellular localization. (Right) Expanded view of nanoparticles shown in left panel 
(Scale bar = 500 nm). Solid arrows point to the nanoparticles.  Labeling is as follows, Nu: 
nucleus, rib: ribosome, ER: endoplasmic reticulum, V: vesicle.   
 
 
Upon the confirmation of the presence of targeted particles inside the tumor following their 
systemic injection, confocal microscopy can validate the utility of Au-PEG-AD as a stain for the 
targeted nanoparticles in the same tumor tissues extracted from the same mice.  
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Method 
 
Fluorescence Microscopy with Au-PEG-AD  
After immersion fixation in 4 % PFA in PBS for 3 d, ~2 cm3 mouse tumor tissue blocks passed through 
an increasing sucrose gradient up to 30 % sucrose, and were later embedded in 9 % gelatin in PBS. The 
gradual freezing of gelatin tissue blocks to -80 °C allowed the generation of 10 µm-thick cryosections. 
After brief rinsing with PBS to remove any surface gelatin as well as fixation with acetone at -20 °C to 
permeabilize the cell membrane, tissue sections underwent staining of PEGylated, adamantane-modified 
gold nanoparticles (Au-PEG-AD) in the dark for 2 h. Rinsing with PBS removed any non-specifically 
bound gold particles, before the mounting of Au-PEG-AD stained tumor sections with 16.7 % (w/v) 
Mowiol 4-88 and 33 % (v/v) glycerol in PBS. A Zeiss LSM 510 confocal scanning microscope served to 
reveal the in vivo tumor biodistribution of the Cy3-siRNA containing targeted nanoparticles (excitation: 
555 nm; emission: 570 nm), whose presence was further confirmed by its colocalization with Au-PEG-
AD (excitation: 488 nm; emission: 507 nm).  
 
Results 
    Cy3        Au-PEG-AD               Merge 
 
 
 
 
 
Figure S3: (Top) Tumor tissue collected from mice receiving intravenous (tail vein) injections of 
Cy3-siRNA containing, targeted nanoparticles. Au-PEG-AD particles (green: middle; emission: 
507 nm) specifically bind to the Cy3-siRNA (orange: left; emission: 570 nm) containing, 
cyclodextrin-based targeted nanoparticles, whose localization was strictly intracellular, as seen 
from the merged bright-field image (right). (Bottom) As a negative control, tumor tissues were 
collected from mice that received intravenous injections of D5W. Au-PEG-AD particles failed to 
stain the tumor tissue in the absence of targeted nanoparticles. (Scale bar = 20 µm)  
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Part V: Staining of biopsy samples with Au-PEG-AD (Patient Pre-treatment samples) 
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Figure S4: Au-PEG-AD staining of CALAA-01 nanoparticles in tumor biopsy samples using 
Au-PEG-AD and DAPI nuclear counter-stain. All pre-treatment samples, including Apre (top 
row), Bpre (second row), C1pre (third row), and C2pre (bottom row), reveal undetectable gold 
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staining. (Scale bar = 20 microns) Legend: M = melanophage (black objects inside the melanoma 
tissue).  
.  
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